Overall rank by patents
#25,702
Across all tracked assignees
USPTO PatentsView assignee record - 10 granted patents across 7 technology areas, active 2023–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G02B (OPTICAL ELEMENTS, SYSTEMS OR APPARATUS).
The verdict
Araceli holds 10 US patents across 7 technology areas, rank #25,702 of 50,000 tracked assignees.
Araceli Biosciences has been granted 10 US utility patents between 2023 and 2025, placing Araceli Biosciences at rank #25,702 across all assignees tracked by PlainPatent. This portfolio spans 7 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.6 claims per patent with primary concentration in G02B (OPTICAL ELEMENTS, SYSTEMS OR APPARATUS). As a US Corporation, Araceli Biosciences is one of the more focused assignees in the PatentsView dataset. By volume, Araceli sits between Apton Biosystems, Inc. (10 patents, rank #25,698) and Arilou Information Security Technologies Ltd. (10 patents, rank #25,706) - the closest US assignees by grant volume. The composite Innovation Score of 48.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2023 through 2025, with 10 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Araceli Biosciences's 17.6 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 7 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Araceli Biosciences against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
APTON BIOSYSTEMS, INC.
10 patents
AQUA BIO TECHNOLOGY ASA
10 patents
AQUAHYDREX PTY LTD
10 patents
AR Packaging Systems AB
10 patents
ARATANA THERAPEUTICS, INC.
10 patents
AREVA Stockage d'Energie
10 patents
ARGOSPECT TECHNOLOGIES INC.
10 patents
ARILOU INFORMATION SECURITY TECHNOLOGIES LTD.
10 patents
ARACELI BIOSCIENCES
10 patents
What this shows Araceli holds 10 patents at rank #25,702, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Araceli's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
48 Top 17% higher than 83% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2023 | 2 | 20.0% |
| 2024 | 4 | 40.0% |
| 2025 | 4 | 40.0% |
Top 7 of 7 technology areas
Overall rank by patents
#25,702
Across all tracked assignees
48.2 out of 100
How to use this portfolio
Araceli's 10 grants land it in the top 17% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.